Peter Pfreundschuh
2018
Compensation breakdown
Non-Equity Incentive Plan | $96,800 |
---|---|
Option Awards | $1,704,505 |
Salary | $156,424 |
Stock Awards | $527,875 |
Other | $197 |
Total | $2,485,800 |
Pfreundschuh received $1.7M in option awards, accounting for 69% of the total pay in 2018.
Pfreundschuh also received $96.8K in non-equity incentive plan, $156.4K in salary, $527.9K in stock awards and $197 in other compensation.
Rankings
In 2018, Peter Pfreundschuh's compensation ranked 4,697th out of 14,244 executives tracked by ExecPay. In other words, Pfreundschuh earned more than 67.0% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 4,697 | 67th |
Manufacturing | 1,767 | 69th |
Chemicals And Allied Products | 639 | 70th |
Drugs | 537 | 70th |
Pharmaceutical Preparations | 414 | 70th |
Pfreundschuh's colleagues
We found six more compensation records of executives who worked with Peter Pfreundschuh at UroGen Pharma Ltd. in 2018.
2018
Ron Bentsur
UroGen Pharma Ltd.
Chief Executive Officer
2018
Stephen Mullennix
UroGen Pharma Ltd.
Chief Financial Officer
2018
Gil Hakim
UroGen Pharma Ltd.
Former President
2018
Gary Titus
UroGen Pharma Ltd.
Chief Financial Officer
2018
Peter Pfreundschuh
UroGen Pharma Ltd.
Chief Financial Officer
2018
Mark Schoenberg
UroGen Pharma Ltd.